Gatifloxacin sesquihydrate

The characteristics of alginate-chitosan films intended for ocular drug delivery of gatifloxacin sesquihydrate were compared with the ionically surface cross-linked films of similar compositions. The effect of polymer ratios and cross-linking was studied relatively to various parameters of formulations including physicochemical, mechanical strength, swelling and bioadhesion. The drug release profiles and drug release mechanisms were compared. The folding endurance, tensile strength, bioadhesive strength considerably increased whereas swelling index, elongation at break decreased with surface cross-linking of the films. Surface cross-linked formulation F3 (2% w/v sodium alginate and 1% w/v chitosan) showed most prolonged drug release of 24 h indicating the potential of surface cross linking of the film to sustain drug release. As per the kinetic models both type of films showed a constant drug release, however the drug release mechanism transformed from erosion to diffusion after cross linking.

BACKGROUND: Many polymeric systems have been used to fabricate ocular inserts for improve ocular bioavailability and retention to drug of which matrix systems have shown advantages of reduce dosing frequency and increased corneal residence time. The objective of the present investigation was to prepare and evaluate ocular inserts of gatifloxacin.

A study was conducted to determine the subacute oral toxicity of LUP-3FDC (a cocktail composed of rifampicin, isoniazid and pyrazinamide) and LUP-Q1 (gatifloxicin sesquihydrate) as well as the potential effects of their combination when administered as repeated sublethal oral (gavage) doses for a period of 90 days in seven (7) groups of Wistar rats. Three (3) additional groups were allowed to live for 28 days after the end of treatment to evaluate the potential reversibility of any toxic effects observed. Mortality was observed at all dose levels. General body weakness and hind limb paralysis (attributable to peripheral neuropathy) were observed in animals administered 1400mg/kg/day LUP-3FDC, 800mg/kg/day LUP 3-FDC+300mg/kg/day LUP Q1 and 1400mg/kg/day LUP-3FDC+300mg/kg/day LUP-Q1. The administration of LUP-3FDC at doses of 1100 or 1400mg/kg/day or a combination of 1400mg/kg/day LUP-3FDC and 300mg/kg/day LUP-Q1 induced an increased incidence of vacuolation in the brain compared to control animals.